Global Information
회사소개 | 문의

바이오시밀러 인덱스 : 세계의 바이오시밀러 파이프라인 추적 조사

Biosimilar Index: Tracking the Biosimilar Development Landscape

리서치사 FirstWord
발행정보 연간구독 상품 코드 298599
페이지 정보 영문 Database + 135 Slides
가격
US $ 19,000 ₩ 21,551,700 Single User License
US $ 34,900 ₩ 39,587,000 Global User License


바이오시밀러 인덱스 : 세계의 바이오시밀러 파이프라인 추적 조사 Biosimilar Index: Tracking the Biosimilar Development Landscape
발행정보 : 페이지 정보 : 영문 Database + 135 Slides

한글목차

세계의 주요 바이오시밀러(Biosimilar) 개발 상황에 관한 업데이트 및 상세한 분석을 전해드립니다.

1. 바이오시밀러 인덱스 : 파이프라인 데이터베이스

2. 데이터베이스의 주요 내용

  • 참조 제품의 브랜드명
  • 적응증 및 참조 제품의 매출 보고
  • 발안 기업
  • 바이오시밀러 개발 기업
  • 개발 기업의 본부 소재지
  • 치료 클래스
  • 주요 지표
  • 응용 형태 및 관리 루트
  • 임상시험 상황
  • 세계의 마케팅 상황
  • 마케팅 합의 및 라이선싱 기회

3. 바이오시밀러 인덱스 : 구도 리뷰

  • 다음과 같은 가장 중요한 구조화 데이터
    • 참조 제품의 매출 데이터
    • 현재 및 향후 시장의 획기적 사건
    • 각 주요 제품의 싱글 뷰 분석
    • 임상시험 활동 및 개발 단계의 플로차트
  • 본 서비스는 임상시험 등록, 기업 커뮤니케이션, 회의 자료, 브로커 분석 및 소셜 미디어 등 광범위한 신뢰성 높은 정보 출처를 인용
  • 지식이 풍부한 전문가에 의한 강력한 해설과 분석
  • Microsoft PowerPoint 형식으로 제시
KSM 14.04.16

영문목차

A new force in biosimilar and NCB drug and market tracking

FirstView's Biosimilar Index is a new, comprehensive drug intelligence service which provides a robust, dynamically updated and highly-detailed insight into the status of leading biosimilar and NCB assets in development worldwide. Exhaustively referenced and sourced, it is one of the most comprehensive analyses of its type providing both on-going tracking of development and interpretation of the commercial and clinical significance.

Two class beating services in one subscription!

Biosimilar Index: Pipeline Database

The Biosimilars Index: Pipeline Database is checked daily. When a significant event happens, the database is updated, thereby ensuring you're up to date with current market dynamics. The database is provided as a dynamic MS Excel™ file with complete data and filter analysis tools included.

Available 24/7 through a secure password protected site, there are no limits on how frequently you can download the XLS file. Having access to the database enables you to see the whole biosimilar and NCB landscape across multiple classes and geographies

Essential details covered in the database include:

  • Brand name(s) of reference products
  • Indications and reported sales for the reference product
  • Originator company
  • Biosimilars development company
  • HQ location of development company
  • Therapy class
  • Key indication(s)
  • Mode of application and route of administration
  • Clinical trials status
  • Global marketing status
  • Marketing agreements and licensing opportunities

Powerful data with intuitive analysis tools

With Biosimilars Index: Pipeline Database at hand, you can effortlessly compare and contrast biosimilars in development by country, originator company, stage of development, condition and therapeutic area. The data is provided in MS Excel™ and comes with filters and search built in. The data can easily be exported to your own analytics package or data visualisation platform.

Biosimilar Index: Landscape Review

What's hot and what's not? The biosimilars sector is constantly evolving. Important research progress, commercial deals and product launches are regularly announced. The Biosimilar Index: Landscape Review strips away market rumour and speculation to tell you exactly what has happened and why it is important.

Published quarterly, the Review is based on the daily-updated research in the Biosimilar Index: Pipeline Database, enhanced by critical insights and understanding from biosimilars experts.

The benefits and features of the Biosimilar Index: Landscape Review...

  • Includes essential structured data including
    • Sales data for reference products
    • Current and future market milestones
    • Individual single view analysis for leading products
    • Clinical trial activities and flow charts of development phase.
  • The service draws on a wide-range of reliable information sources such as clinical trial registries, company communications, conference proceedings, broker analysis and social media.
  • Includes powerful interpretation and analysis by knowledgeable experts to ensure that developments are scrutinised and the implications highlighted.
  • Presented in MS PowerPoint™ to bring clarity to the extensive charting and tables provided which can be incorporated into your own presentations

Key benefits and features:

With Biosimilar Index you can...

  • Understand the biosimilar and NCB development landscape through comprehensive coverage of the pipelines of all major biosimilar developers worldwide
  • Drill down to discover the levels of potential biosimilar competition by therapy area, drug class status and geography
  • Establish the level of biosimilar competition for leading biologic brands
  • Learn which biosimilar developers are potential future competitors or collaborators
  • Identify the biosimilar and NCB portfolios of over 130 companies and discover the leaders in product development for which products/therapy areas
  • Know where the development hotspots are and what research is taking place.

The Biosimilar Index is feature rich...

  • Includes both structured data and commercial interpretation
  • The Biosimilar Index: Pipeline Database covers all significant biosimilar products and is updated daily. Available 24/7 in MS Excel™ with unlimited downloads which can be incorporated into your own analytics package or visualisation software
  • The Biosimilar Index: Landscape Review provides and insightful quarterly analysis which identifies the developments that are really important
  • Biosimilar Index is Informed by a wide-range of respected sources with expert internal and external inputs and oversight

A service for the whole industry

Whether you work in big pharma, a biosimilars development company, a clinical service organisation, a regulatory body or in commercial investment and finance, the Biosimilar Index provides a clear window on the world of biosimilar drugs and their developers.

With the Biosimilar Index you are always in the know!

Table of Contents

Introduction

Executive summary

Reference medicinal product data

Market milestones; Q1 2013 - Q1 2014

Potential future milestones; Q2 2014 - Q4 2014

Biosimilar programme analysis

  • Pipeline summary by molecule
  • Clinical trials by molecule

Appendix

  • Data sources
  • Definitions and terminology
  • Disclaimer

[139 slides]

List of Companies

  • AbbVie
  • Idec Pharmaceuticals
  • Sanofi
  • Genentech
  • Centocor
  • Immunex
  • Amgen Genentech
  • Kirin Holdings
  • Novo Nordisk
  • Biogen Idec
  • Eli Lilly
  • Sanofi
  • Novo Nordisk
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research